FBXW7 (F8B6C) Rabbit Monoclonal Antibody #49367
- WB
- IP
Product Specifications
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 100 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
FBXW7 is one of the most frequently mutated genes in human cancers, with most mutations occurring within the WD40 domain; therefore, preventing FBXW7 from binding to target substrates and driving hyperproliferation and genomic instability (8-10). FBXW7 mutations are found in over 30% of T-cell acute lymphoblastic leukemia cases (11), and loss of FBXW7 is correlated with poor clinical outcome in colorectal cancer (12). Studies have also shown that FBXW7 inactivation can promote drug resistance through several mechanisms such as apoptosis evasion (via stabilization of Mcl-1) or epithelial-mesenchymal transition (via stabilization of ZEB2) (13,14). Additionally, because FBXW7 regulates SREBP-1 and c-Myc, its dysregulation may also be linked to disorders involving lipid and glucose metabolism (15).
- Akhoondi, S. et al. (2007) Cancer Res 67, 9006-12.
- Welcker, M. and Clurman, B.E. (2008) Nat Rev Cancer 8, 83-93.
- Hao, B. et al. (2007) Mol Cell 26, 131-43.
- Nash, P. et al. (2001) Nature 414, 514-21.
- Zhou, Z. et al. (2015) Oncol Rep 34, 2215-24.
- de la Cova, C.C. (2023) Cells 12, 2141. doi: 10.3390/cells12172141.
- van Drogen, F. et al. (2006) Mol Cell 23, 37-48.
- Yeh, C.H. et al. (2018) Mol Cancer 17, 115.
- Fan, J. et al. (2022) Mol Cancer 21, 87.
- Shen, W. et al. (2022) Front Oncol 12, 880077.
- Yeh, C.H. et al. (2016) Proc Natl Acad Sci USA 113, 6731-6.
- Rahmanian, M. et al. (2025) Cancer Treat Res Commun 45, 100988.
- Chen, S. et al. (2023) Front Oncol 13, 1147239.
- Wang, W. et al. (2023) Front Pharmacol 14, 1278056.
- Shimizu, K. et al. (2018) Cell Signal 46, 15-22.
Alternate Names
AGO; archipelago; Archipelago homolog; archipelago, Drosophila, homolog of; CDC4; DKFZp686F23254; F-box and WD repeat domain containing 7; F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase; F-box and WD-40 domain protein 7 (archipelago homolog, Drosophila); F-box and WD-40 domain-containing protein 7; F-box protein FBW7; F-box protein FBX30; F-box protein SEL-10; F-box/WD repeat-containing protein 7; FBW6; FBW7; FBX30; FBXO30; FBXW6; FBXW7; FLJ16457; hAgo; hCdc4; homolog of C elegans sel-10; SEL-10; SEL10
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.